☕ Chemoprevention of HCC
Top strategies:
✅ HBV vaccination ↓ HCC by 80–90%
✅ HBV/HCV antivirals cut risk by ~70%
💊 Statins & aspirin lower HCC incidence (30–40%) via
anti-inflammatory, anti-fibrotic effects
⚕️ GLP-1RAs & SGLT2i show promise in MASLD
☕ Coffee & Mediterranean diet protective
🏁 Most effective: viral control + metabolic management.
📢 AASLD/IDSA 2025 Chronic HBV
Pregnancy – MTCT Prevention
▪ Start TDF (preferred) or TAF when HBV DNA >200,000 IU/mL
▪ Begin at week 28 (consider week 16 if HBIG unavailable)
▪ Stop at delivery if no other indication; monitor closely
2025 guidelines standardize timing, incorporate TAF, clarify earlier start options, and define stop/monitoring strategy—supporting globally applicable MTCT prevention.
AASLD 2025 | SOLSTICE Phase 2 Trial
Tobevibart (anti-HBsAg mAb) ± Elebsiran (siRNA) in chronic #HepatitisD:
✅ Week 48 undetectable HDV RNA: 66% (combo) vs 48% (monotherapy)
✅ HBsAg < 10 IU/mL: 91% vs 21%
💉Safe & well-tolerated; no ALT flares.
A promising dual HBV/HDV targeted approach.
GastroAGI